Turkish Neurosurgery
Efficacy and Safety Assessment of LVIS JR Device in Treating Wide-Neck Aneurysms – A Comprehensive Systematic Review and Single-Arm Meta-Analysis
Marcelo Porto Sousa1, Guilherme Nunes Marques1, Livia Viviani de Abreu1, Filipi Fim Andreão1, Leonardo de Barros Oliveira2, Gabriel Verly1, Sávio Batista1, Guilherme Melo Silva1, Raphael Muszkat Besborodco3, Raphael Bertani4
1University Federal of Rio de Janeiro, Faculty of Medicine, Rio de Janeiro - Rio de Janeiro,
2State University of Ponta Grossa, Faculty of Medicine, Ponta Grossa - Paraná,
3NYU Langone Health, Rusk Rehabilitation, New York - New York,
4University of São Paulo, Department of Neurosurgery, São Paulo - São Paulo,
DOI: 10.5137/1019-5149.JTN.46167-23.2

Introduction: Wide-neck aneurysms pose a daunting challenge to endovascular neurosurgeons. Thus, the Low-profile Visualized Intraluminal Support Junior (LVIS Jr) stent from MicroVention-Terumo has emerged as a promising treatment option. This meta-analysis aims to evaluate the usability and effectiveness of this technology in managing wide-neck aneurysms. Methods: We systematically searched in PubMed, Embase, and Web of Science databases, comprising studies with outcomes related to LVIS Jr use in wide-neck aneurysms. Data was extracted from the selected articles and subjected to statistical analysis. Additionally, the ROBINS-I tool was employed for quality assessment. Results: Among 886 initially identified articles, 20 studies met our inclusion criteria, comprising a total of 557 patients. Our analysis revealed a 96% final occlusion rate under common effects and 93% under random effects, with substantial heterogeneity (I² = 69%), and good clinical outcomes were observed in 99% of cases with low heterogeneity (I² = 27%). Mortality rates were extremely low, with only one reported death out of 499 patients across 18 studies, resulting in a 0% mortality rate for common and random effects, and no heterogeneity (I² = 0). Complications occurred in 44 of 482 patients, yielding a 6% rate in the common effect model and 6% in the random effects model, with nonsignificant heterogeneity (I² = 25%). Conclusion: A favorable rate of final occlusion and good clinical outcomes was observed with LVIS Jr. Moreover, the low mortality and complication rates highlight its safety.

Corresponding author : Marcelo Porto Sousa